Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer

Final appraisal determination

Final appraisal determination document (PDF 223 KB)

Committee papers (PDF 361 KB)

Final appraisal determination

Final appraisal determination document (PDF 225 KB)

Committee papers (PDF 310 KB)

Equality Impact Assessment (Guidance development) (PDF 168 KB)

Appraisal consultation

Appraisal consultation document (PDF 207 KB)

Committee papers information

Committee papers (PDF 4.41 MB)

Equality impact assessment form - scoping (PDF 67 KB)

Final scope (PDF 102 KB)

Final matrix (PDF 15 KB)

NICE response to comments on the draft scope and provisional matrix (PDF 131 KB)

Lung cancer (non-small-cell, anaplastic lymphoma kinase positive, previously treated) - ceritinib: provisional matrix (pre-referral) March 2014 (PDF 98 KB)

Lung cancer (non-small-cell, anaplastic lymphoma kinase positive, previously treated) - ceritinib: draft scope for consultation (pre-referral) March 2014 (PDF 112 KB)